42164 Federal Register / Vol. 83, No. 161 / Monday, August 20, 2018 / Notices 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–488P] 

Proposed Aggregate Production 

Quotas for Schedule I and II Controlled 

Substances and Assessment of 

Annual Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2019 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Notice with request for 

comments. 

SUMMARY: The Drug Enforcement 

Administration (DEA) proposes to 

establish the 2019 aggregate production 

quotas for controlled substances in 

schedules I and II of the Controlled 

Substances Act and assessment of 

annual needs for the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine. 

DATES: Interested persons may file 

written comments on this notice in 

accordance with 21 CFR 1303.11(c) and 

1315.11(d). Electronic comments must 

be submitted, and written comments 

must be postmarked, on or before 

September 19, 2018. Commenters 

should be aware that the electronic 

Federal Docket Management System 

will not accept comments after 11:59 

p.m. Eastern Time on the last day of the 

comment period. 

Based on comments received in 

response to this notice, the 

Administrator may hold a public 

hearing on one or more issues raised. In 

the event the Administrator decides in 

his sole discretion to hold such a 

hearing, the Administrator will publish 

a notice of any such hearing in the 

Federal Register. After consideration of 

any comments or objections, or after a 

hearing, if one is held, the 

Administrator will publish in the 

Federal Register a final order 

establishing the 2019 aggregate 

production quotas for schedule I and II 

controlled substances, and an 

assessment of annual needs for the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–488P’’ on all correspondence, 

including any attachments. The Drug 

Enforcement Administration encourages 

that all comments be submitted 

electronically through the Federal 

eRulemaking Portal, which provides the 

ability to type short comments directly 

into the comment field on the web page 

or attach a file for lengthier comments. 

Please go to http://www.regulations.gov 

and follow the online instructions at 

that site for submitting comments. Upon 

completion of your submission you will 

receive a Comment Tracking Number for 

your comment. Please be aware that 

submitted comments are not 

instantaneously available for public 

view on regulations.gov. If you have 

received a Comment Tracking Number, 

your comment has been successfully 

submitted and there is no need to 

resubmit the same comment. Paper 

comments that duplicate electronic 

submissions are not necessary and are 

discouraged. Should you wish to mail a 

paper comment in lieu of an electronic 

comment, it should be sent via regular 

or express mail to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

FOR FURTHER INFORMATION CONTACT: 

Thomas D. Sonnen, Diversion Control 

Division, Drug Enforcement 

Administration; Mailing Address: 8701 

Morrissette Drive, Springfield, Virginia 

22152, Telephone: (202) 598–6812. 

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments 

Please note that all comments 

received in response to this docket are 

considered part of the public record. 

They will, unless reasonable cause is 

given, be made available by the Drug 

Enforcement Administration (DEA) for 

public inspection online at http://

www.regulations.gov. Such information 

includes personal identifying 

information (such as your name, 

address, etc.) voluntarily submitted by 

the commenter. 

The Freedom of Information Act 

(FOIA) applies to all comments 

received. If you want to submit personal 

identifying information (such as your 

name, address, etc.) as part of your 

comment, but do not want it to be made 

publicly available, you must include the 

phrase ‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all the personal identifying information 

you do not want made publicly 

available in the first paragraph of your 

comment and identify what information 

you want redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be made 

publicly available, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify confidential 

business information to be redacted 

within the comment. 

Comments containing personal 

identifying information or confidential 

business information identified and 

located as directed above will generally 

be made available in redacted form. If a 

comment contains so much confidential 

business information or personal 

identifying information that it cannot be 

effectively redacted, all or part of that 

comment may not be made publicly 

available. Comments posted to http://

www.regulations.gov may include any 

personal identifying information (such 

as name, address, and phone number) 

included in the text of your electronic 

submission that is not identified as 

directed above as confidential. 

An electronic copy of this document 

is available at http://

www.regulations.gov for easy reference. 

Legal Authority 

Section 306 of the Controlled 

Substances Act (CSA) (21 U.S.C. 826) 

requires the Attorney General to 

establish aggregate production quotas 

for each basic class of controlled 

substance listed in schedules I and II 

and for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. The Attorney 

General has delegated this function to 

the Administrator of the DEA pursuant 

to 28 CFR 0.100. 

Analysis for Proposed 2019 Aggregate 

Production Quotas and Assessment of 

Annual Needs 

The proposed year 2019 aggregate 

production quotas and assessment of 

annual needs represent those quantities 

of schedule I and II controlled 

substances, and the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine, to be 

manufactured in the United States in 

2019 to provide for the estimated 

medical, scientific, research, and 

industrial needs of the United States, 

lawful export requirements, and the 

establishment and maintenance of 

reserve stocks. These quotas include 

imports of ephedrine, pseudoephedrine, 

and phenylpropanolamine, but do not 

include imports of controlled 

substances for use in industrial 

processes. 

In determining the proposed 2019 

aggregate production quotas and 

assessment of annual needs, the Acting 

Administrator has taken into account 

the criteria in 21 U.S.C. 826(a) and 

factors set forth in 21 CFR 1303.11 

(aggregate production quotas for 

controlled substances) and 21 CFR 

1315.11 (assessment of annual needs for 

ephedrine, pseudoephedrine, and 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 161 / Monday, August 20, 2018 / Notices 42165 

phenylpropanolamine). The DEA 

proposes the aggregate production 

quotas and assessment of annual needs 

for 2019 by considering: (1) Total net 

disposal of each class or chemical by all 

manufacturers and chemical importers 

during the current and two preceding 

years; (2) trends in the national rate of 

net disposal of the class or chemical; (3) 

total actual (or estimated) inventories of 

the class or chemical and of all 

substances manufactured from the class 

or chemical, and trends in inventory 

accumulation; (4) projected demand for 

each class or chemical as indicated by 

procurement and import quotas 

requested in accordance with 21 CFR 

1303.12, 1315.32, and 1315.34; and (5) 

other factors affecting medical, 

scientific, research, and industrial needs 

of the United States and lawful export 

requirements, as the Acting 

Administrator finds relevant. These 

quotas do not include imports of 

controlled substances for use in 

industrial processes. 

Other factors the Acting 

Administrator considered in calculating 

the aggregate production quotas, but not 

the assessment of annual needs, include 

product development requirements of 

both bulk and finished dosage form 

manufacturers, and other pertinent 

information. In determining the 

proposed 2019 assessment of annual 

needs, the DEA used the calculation 

methodology previously described in 

the 2010 and 2011 assessment of annual 

needs (74 FR 60294, Nov. 20, 2009, and 

75 FR 79407, Dec. 20, 2010, 

respectively). 

On July 16, 2018, DEA published a 

final rule regarding controlled 

substances quotas with an effective date 

of August 15, 2018 (‘‘Controlled 

Substances Quotas Final Rule’’). 83 FR 

32784. The Controlled Substances 

Quotas Final Rule added two factors for 

DEA to consider when setting aggregate 

production quotas and assessments of 

annual needs. These additional factors 

are: (1) The extent of any diversion of 

the controlled substance in the class; 

and (2) relevant information obtained 

from the Department of Health and 

Human Services, including from the 

Food and Drug Administration, the 

Centers for Disease Control and 

Prevention, and the Centers for 

Medicare and Medicaid Services, and 

relevant information obtained from the 

states. The proposed aggregate quotas 

for 2019 in this notice were determined 

with consideration of the factors in 

effect prior to the effective date of the 

Controlled Substances Quotas Final 

Rule. 

The Acting Administrator, therefore, 

proposes to establish the 2019 aggregate 

production quotas for certain schedule I 

and II controlled substances and 

assessment of annual needs for the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine, expressed in 

grams of anhydrous acid or base, as 

follows: 

Basic class 

Proposed 

2019 quotas 

(g) 

Schedule I 

1-[1-(2-Thienyl)cyclohexyl]pyrrolidine .................................................................................................................................................. 20 

1-(1-Phenylcyclohexyl)pyrrolidine ........................................................................................................................................................ 15 

1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine .................................................................................................................................. 10 

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ............................................................................................................................ 30 

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ........................................................................................................................... 30 

1-Benzylpiperazine .............................................................................................................................................................................. 25 

1-Methyl-4-phenyl-4-propionoxypiperidine ........................................................................................................................................... 10 

1-[1-(2-Thienyl)cyclohexyl]piperidine ................................................................................................................................................... 15 

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E) .......................................................................................................................... 30 

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D) ....................................................................................................................... 30 

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N) ......................................................................................................................... 30 

2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C–P) ..................................................................................................................... 30 

2-(2,5-Dimethoxyphenyl)ethanamine (2C–H) ...................................................................................................................................... 30 

2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B–NBOMe; 2C–B–NBOMe; 25B; Cimbi-36) ...................... 30 

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C) ........................................................................................................................ 30 

2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C–NBOMe; 2C–C–NBOMe; 25C; Cimbi-82) ..................... 25 

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I) ............................................................................................................................. 30 

2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C–I–NBOMe; 25I; Cimbi-5) ................................ 30 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ...................................................................................................................................... 25 

2,5-Dimethoxy-4-n-propylthiophenethylamine ..................................................................................................................................... 25 

2,5-Dimethoxyamphetamine ................................................................................................................................................................ 25 

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2) ............................................................................................................... 30 

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4) ........................................................................................................ 30 

3,4,5-Trimethoxyamphetamine ............................................................................................................................................................ 30 

3,4-Methylenedioxyamphetamine (MDA) ............................................................................................................................................ 55 

3,4-Methylenedioxymethamphetamine (MDMA) ................................................................................................................................. 50 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ............................................................................................................................. 40 

3,4-Methylenedioxy-N-methylcathinone (methylone) .......................................................................................................................... 40 

3,4-Methylenedioxypyrovalerone (MDPV) ........................................................................................................................................... 35 

3–FMC; 3-Fluoro-N-methylcathinone .................................................................................................................................................. 25 

3-Methylfentanyl ................................................................................................................................................................................... 30 

3-Methylthiofentanyl ............................................................................................................................................................................. 30 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ...................................................................................................................................... 30 

4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ................................................................................................................................. 25 

1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboximide ............................................................................................... 25 

4-Fluoroisobutyryl fentanyl ................................................................................................................................................................... 30 

4–FMC; Flephedrone ........................................................................................................................................................................... 25 

4–MEC; 4-Methyl-N-ethylcathinone ..................................................................................................................................................... 25 

4-Methoxyamphetamine ...................................................................................................................................................................... 150 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ...................................................................................................................................... 25 


daltland on DSKBBV9HB2PROD with NOTICES
42166 Federal Register / Vol. 83, No. 161 / Monday, August 20, 2018 / Notices 

Basic class 

Proposed 

2019 quotas 

(g) 

4-Methylaminorex ................................................................................................................................................................................ 25 

4-Methyl-N-methylcathinone (mephedrone) ........................................................................................................................................ 45 

4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) ............................................................................................................................... 25 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ......................................................................................................... 50 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8-homolog) .......................... 40 

N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide ...................................................................... 25 

1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3carboximide .......................................................................... 25 

5F–ADB; 5F–MDMB–PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .......................... 30 

5F–AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) .................................................................. 30 

5F–APINACA; 5F–AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ....................................................... 30 

5-Fluoro-PB–22; 5F–PB–22 ................................................................................................................................................................ 20 

5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ............................................ 25 

5-Methoxy-3,4-methylenedioxyamphetamine ...................................................................................................................................... 25 

5-Methoxy-N,N-diisopropyltryptamine .................................................................................................................................................. 25 

5-Methoxy-N,N-dimethyltryptamine ..................................................................................................................................................... 25 

AB–CHMINACA ................................................................................................................................................................................... 30 

AB–FUBINACA .................................................................................................................................................................................... 50 

AB–PINACA ......................................................................................................................................................................................... 30 

ADB–FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ................................. 30 

Acetyl Fentanyl .................................................................................................................................................................................... 100 

Acetyl-alpha-methylfentanyl ................................................................................................................................................................. 30 

Acetyldihydrocodeine ........................................................................................................................................................................... 30 

Acetylmethadol .................................................................................................................................................................................... 2 

Acryl Fentanyl ...................................................................................................................................................................................... 25 

ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ..................................................... 50 

AH–7921 .............................................................................................................................................................................................. 30 

Allylprodine .......................................................................................................................................................................................... 2 

Alphacetylmethadol .............................................................................................................................................................................. 2 

alpha-Ethyltryptamine .......................................................................................................................................................................... 25 

Alphameprodine ................................................................................................................................................................................... 2 

Alphamethadol ..................................................................................................................................................................................... 2 

alpha-Methylfentanyl ............................................................................................................................................................................ 30 

alpha-Methylthiofentanyl ...................................................................................................................................................................... 30 

alpha-Methyltryptamine (AMT) ............................................................................................................................................................ 25 

alpha-Pyrrolidinobutiophenone (a-PBP) .............................................................................................................................................. 25 

alpha-Pyrrolidinopentiophenone (a-PVP) ............................................................................................................................................ 25 

Aminorex .............................................................................................................................................................................................. 25 

Anileridine ............................................................................................................................................................................................ 20 

APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) ......................................................................................... 25 

Benzylmorphine ................................................................................................................................................................................... 30 

Betacetylmethadol ............................................................................................................................................................................... 2 

beta-Hydroxy-3-methylfentanyl ............................................................................................................................................................ 30 

beta-Hydroxyfentanyl ........................................................................................................................................................................... 30 

beta-Hydroxythiofentanyl ..................................................................................................................................................................... 30 

Betameprodine ..................................................................................................................................................................................... 2 

Betamethadol ....................................................................................................................................................................................... 4 

Betaprodine .......................................................................................................................................................................................... 2 

Bufotenine ............................................................................................................................................................................................ 3 

Butylone ............................................................................................................................................................................................... 25 

Butyryl fentanyl .................................................................................................................................................................................... 30 

Cathinone ............................................................................................................................................................................................. 24 

Codeine methylbromide ....................................................................................................................................................................... 30 

Codeine-N-oxide .................................................................................................................................................................................. 192 

Cyclopropyl Fentanyl ........................................................................................................................................................................... 20 

Desomorphine ...................................................................................................................................................................................... 25 

Diapromide ........................................................................................................................................................................................... 20 

Diethylthiambutene .............................................................................................................................................................................. 20 

Diethyltryptamine ................................................................................................................................................................................. 25 

Difenoxin .............................................................................................................................................................................................. 8,225 

Dihydromorphine .................................................................................................................................................................................. 753,500 

Dimethyltryptamine .............................................................................................................................................................................. 50 

Dipipanone ........................................................................................................................................................................................... 5 

Etorphine .............................................................................................................................................................................................. 30 

Fenethylline .......................................................................................................................................................................................... 30 

Fentanyl related substances ................................................................................................................................................................ 25 

Furanyl fentanyl ................................................................................................................................................................................... 30 

gamma-Hydroxybutyric acid ................................................................................................................................................................ 33,417,000 

Heroin .................................................................................................................................................................................................. 45 

Hydromorphinol .................................................................................................................................................................................... 40 

Hydroxypethidine ................................................................................................................................................................................. 2 

Ibogaine ............................................................................................................................................................................................... 30 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 161 / Monday, August 20, 2018 / Notices 42167 

Basic class 

Proposed 

2019 quotas 

(g) 

Isobutyryl Fentanyl ............................................................................................................................................................................... 25 

JWH–018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) ..................................................................................................................... 35 

JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) .......................................................................................................................................... 45 

JWH–073 (1-Butyl-3-(1-naphthoyl)indole) ........................................................................................................................................... 45 

JWH–081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) ...................................................................................................................... 30 

JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) .......................................................................................................................... 30 

JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) .............................................................................................................. 35 

JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) ........................................................................................................................... 30 

JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) ....................................................................................................................... 30 

JWH–398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) ........................................................................................................................... 30 

Lysergic acid diethylamide (LSD) ........................................................................................................................................................ 40 

MAB–CHMINACA; ADB–CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3- 

carboxamide) .................................................................................................................................................................................... 30 

MDMB–CHMICA; MMB–CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) ............... 30 

MDMB–FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .......................................... 30 

Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate .................................................................................. 25 

Marihuana ............................................................................................................................................................................................ 2,450,000 

Mecloqualone ....................................................................................................................................................................................... 30 

Mescaline ............................................................................................................................................................................................. 25 

Methaqualone ...................................................................................................................................................................................... 60 

Methcathinone ..................................................................................................................................................................................... 25 

Methyldesorphine ................................................................................................................................................................................. 5 

Methyldihydromorphine ........................................................................................................................................................................ 2 

Morphine methylbromide ..................................................................................................................................................................... 5 

Morphine methylsulfonate .................................................................................................................................................................... 5 

Morphine-N-oxide ................................................................................................................................................................................ 150 

Naphthalen-1-yl 1-(5-fluorpentyl)-1H-indole-3-carboxylate .................................................................................................................. 25 

N,N-Dimethylamphetamine .................................................................................................................................................................. 25 

Naphyrone ........................................................................................................................................................................................... 25 

N-Ethyl-1-phenylcyclohexylamine ........................................................................................................................................................ 5 

N-Ethyl-3-piperidyl benzilate ................................................................................................................................................................ 10 

N-Ethylamphetamine ........................................................................................................................................................................... 24 

N-Hydroxy-3,4-methylenedioxyamphetamine ...................................................................................................................................... 24 

Noracymethadol ................................................................................................................................................................................... 2 

Norlevorphanol ..................................................................................................................................................................................... 55 

Normethadone ..................................................................................................................................................................................... 2 

Normorphine ........................................................................................................................................................................................ 40 

Ocfentanil ............................................................................................................................................................................................. 25 

Para-fluorofentanyl ............................................................................................................................................................................... 25 

Para-flourobutyryl fentanyl ................................................................................................................................................................... 25 

Parahexyl ............................................................................................................................................................................................. 5 

PB–22; QUPIC ..................................................................................................................................................................................... 20 

Pentedrone .......................................................................................................................................................................................... 25 

Pentylone ............................................................................................................................................................................................. 25 

Phenomorphan .................................................................................................................................................................................... 2 

Pholcodine ........................................................................................................................................................................................... 5 

Psilocybin ............................................................................................................................................................................................. 30 

Psilocyn ................................................................................................................................................................................................ 50 

SR–18 and RCS–8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) ......................................................................................... 45 

SR–19 and RCS–4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) ............................................................................................................ 30 

Tetrahydrocannabinols ........................................................................................................................................................................ 384,460 

Tetrahydrofuranyl fentanyl ................................................................................................................................................................... 5 

Thiofentanyl ......................................................................................................................................................................................... 25 

THJ–2201 ( [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) .................................................................................... 30 

Tilidine .................................................................................................................................................................................................. 25 

Trimeperidine ....................................................................................................................................................................................... 2 

UR–144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ..................................................................................... 25 

U–47700 .............................................................................................................................................................................................. 30 

Valeryl fentanyl .................................................................................................................................................................................... 25 

Schedule II 

1-Phenylcyclohexylamine .................................................................................................................................................................... 15 

1-Piperidinocyclohexanecarbonitrile .................................................................................................................................................... 25 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ......................................................................................................................................... 1,185,000 

Alfentanil .............................................................................................................................................................................................. 6,200 

Alphaprodine ........................................................................................................................................................................................ 2 

Amobarbital .......................................................................................................................................................................................... 20,100 

Amphetamine (for conversion) ............................................................................................................................................................ 12,000,000 

Amphetamine (for sale) ....................................................................................................................................................................... 42,400,000 

Carfentanil ............................................................................................................................................................................................ 20 


daltland on DSKBBV9HB2PROD with NOTICES
42168 Federal Register / Vol. 83, No. 161 / Monday, August 20, 2018 / Notices 

Basic class 

Proposed 

2019 quotas 

(g) 

Cocaine ................................................................................................................................................................................................ 92,120 

Codeine (for conversion) ..................................................................................................................................................................... 13,536,000 

Codeine (for sale) ................................................................................................................................................................................ 40,015,800 

Dextropropoxyphene ............................................................................................................................................................................ 35 

Dihydrocodeine .................................................................................................................................................................................... 238,466 

Dihydroetorphine .................................................................................................................................................................................. 2 

Diphenoxylate (for conversion) ............................................................................................................................................................ 14,100 

Diphenoxylate (for sale) ....................................................................................................................................................................... 770,800 

Ecgonine .............................................................................................................................................................................................. 88,134 

Ethylmorphine ...................................................................................................................................................................................... 30 

Etorphine hydrochloride ....................................................................................................................................................................... 32 

Fentanyl ............................................................................................................................................................................................... 1,185,000 

Glutethimide ......................................................................................................................................................................................... 2 

Hydrocodone (for conversion) ............................................................................................................................................................. 5,000 

Hydrocodone (for sale) ........................................................................................................................................................................ 44,710,000 

Hydromorphone ................................................................................................................................................................................... 4,071,000 

Isomethadone ...................................................................................................................................................................................... 30 

Levo-alphacetylmethadol (LAAM) ........................................................................................................................................................ 5 

Levomethorphan .................................................................................................................................................................................. 4,000 

Levorphanol ......................................................................................................................................................................................... 34,000 

Lisdexamfetamine ................................................................................................................................................................................ 19,000,000 

Meperidine ........................................................................................................................................................................................... 1,580,000 

Meperidine Intermediate-A .................................................................................................................................................................. 30 

Meperidine Intermediate-B .................................................................................................................................................................. 30 

Meperidine Intermediate-C .................................................................................................................................................................. 30 

Metazocine ........................................................................................................................................................................................... 15 

Methadone (for sale) ........................................................................................................................................................................... 22,278,000 

Methadone Intermediate ...................................................................................................................................................................... 24,064,000 

Methamphetamine ............................................................................................................................................................................... 1,446,754 

[846,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 564,000 grams for methamphetamine

mostly for conversion to a schedule III product; and 36,754 grams for methamphetamine (for sale)] 

Methylphenidate ................................................................................................................................................................................... 64,600,000 

Morphine (for conversion) .................................................................................................................................................................... 4,089,000 

Morphine (for sale) .............................................................................................................................................................................. 31,456,000 

Nabilone ............................................................................................................................................................................................... 62,000 

Noroxymorphone (for conversion) ....................................................................................................................................................... 19,169,340 

Noroxymorphone (for sale) .................................................................................................................................................................. 376,000 

Opium (powder) ................................................................................................................................................................................... 84,600 

Opium (tincture) ................................................................................................................................................................................... 530,837 

Oripavine .............................................................................................................................................................................................. 28,705,000 

Oxycodone (for conversion) ................................................................................................................................................................ 2,081,000 

Oxycodone (for sale) ........................................................................................................................................................................... 85,578,000 

Oxymorphone (for conversion) ............................................................................................................................................................ 24,525,540 

Oxymorphone (for sale) ....................................................................................................................................................................... 2,880,000 

Pentobarbital ........................................................................................................................................................................................ 25,850,000 

Phenazocine ........................................................................................................................................................................................ 5 

Phencyclidine ....................................................................................................................................................................................... 35 

Phenmetrazine ..................................................................................................................................................................................... 25 

Phenylacetone ..................................................................................................................................................................................... 40 

Racemethorphan ................................................................................................................................................................................. 5 

Racemorphan ...................................................................................................................................................................................... 5 

Remifentanil ......................................................................................................................................................................................... 3,000 

Secobarbital ......................................................................................................................................................................................... 172,100 

Sufentanil ............................................................................................................................................................................................. 1,880 

Tapentadol ........................................................................................................................................................................................... 18,388,280 

Thebaine .............................................................................................................................................................................................. 84,600,000 

List I Chemicals 

Ephedrine (for conversion) .................................................................................................................................................................. 25 

Ephedrine (for sale) ............................................................................................................................................................................. 4,136,000 

Phenylpropanolamine (for conversion) ................................................................................................................................................ 14,100,000 

Phenylpropanolamine (for sale) ........................................................................................................................................................... 7,990,000 

Pseudoephedrine (for conversion) ...................................................................................................................................................... 1,000 

Pseudoephedrine (for sale) ................................................................................................................................................................. 174,246,000 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 161 / Monday, August 20, 2018 / Notices 42169 

The Acting Administrator further 

proposes that aggregate production 

quotas for all other schedule I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 remain at 

zero. In accordance with 21 CFR 

1303.13 and 21 CFR 1315.13, upon 

consideration of the relevant factors, the 

Acting Administrator may adjust the 

2019 aggregate production quotas and 

assessment of annual needs as needed. 

Conclusion 

After consideration of any comments 

or objections, or after a hearing, if one 

is held, the Acting Administrator will 

issue and publish in the Federal 

Register a final order establishing the 

2019 aggregate production quotas for 

controlled substances in schedules I and 

II and establishing an assessment of 

annual needs for the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine, 21 CFR 

1303.11(c) and 1315.11(f). 

Dated: August 14, 2018. 

Uttam Dhillon, 

Acting Administrator. 

[FR Doc. 2018–17893 Filed 8–17–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

[OMB Number 1103–0093] 

Agency Information Collection 

Activities; Proposed eCollection 

eComments Requested; Revision of a 

Previously Approved Collection; COPS 

Extension Request Form 

AGENCY: Community Oriented Policing 

Services (COPS) Office, Department of 

Justice. 

ACTION: 60-Day notice. 

SUMMARY: The Department of Justice 

(DOJ), Community Oriented Policing 

Services (COPS) Office, will be 

submitting the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and approval in accordance with 

the Paperwork Reduction Act of 1995. 

DATES: Comments are encouraged and 

will be accepted for 60 days until 

October 19, 2018. 

FOR FURTHER INFORMATION CONTACT: If 

you have additional comments 

especially on the estimated public 

burden or associated response time, 

suggestions, or need a copy of the 

proposed information collection 

instrument with instructions or 

additional information, please contact 

Lashon M. Hilliard, Policy Analyst, 

Department of Justice, Community 

Oriented Policing Services (COPS) 

Office, 145 N Street NE, Washington, DC 

20530 (202–514–6563). 

SUPPLEMENTARY INFORMATION: Written 

comments and suggestions from the 

public and affected agencies concerning 

the proposed collection of information 

are encouraged. Your comments should 

address one or more of the following 

four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the Bureau of Justice 

Statistics, including whether the 

information will have practical utility; 

—Evaluate the accuracy of the agency’s 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

—Evaluate whether and if so how the 

quality, utility, and clarity of the 

information to be collected can be 

enhanced; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of This Information 

Collection 

1. Type of Information Collection: 

Revision of a currently approved 

collection, with change; comments 

requested. 

2. The Title of the Form/Collection: 

COPS Extension Request Form. 

3. The agency form number, if any, 

and the applicable component of the 

Department sponsoring the collection: 

None. U.S. Department of Justice, 

Community Oriented Policing Services 

(COPS) Office. 

4. Affected public who will be asked 

or required to respond, as well as a brief 

abstract: Law enforcement agencies and 

other COPS grants recipients that have 

grants expiring within 90 days of the 

date of the form/request. The extension 

request form will allow recipients of 

COPS grants the opportunity to request 

a ‘‘no-cost’’ time extension in order to 

complete the federal funding period and 

requirements for their grant/cooperative 

agreement award. Requesting and/or 

receiving a time extension will not 

provide additional funding. 

5. An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond: It is estimated that 

approximately 2,700 respondents 

annually will complete the form within 

30 minutes. 

6. An estimate of the total public 

burden (in hours) associated with the 

collection: 1,350 total annual burden 

hours (0.5 hours × 2700 respondents + 

1,350 total burden hours). 

If additional information is required 

contact: Melody Braswell, Department 

Clearance Officer, United States 

Department of Justice, Justice 

Management Division, Policy and 

Planning Staff, Two Constitution 

Square, 145 N Street NE, Washington, 

DC 20530. 

Dated: August 14, 2018. 

Melody Braswell, 

Department Clearance Officer for PRA, U.S. 

Department of Justice. 

[FR Doc. 2018–17864 Filed 8–17–18; 8:45 am] 

BILLING CODE 4410–AT–P 

DEPARTMENT OF JUSTICE 

[OMB Number 1103–0093] 

Agency Information Collection 

Activities; Proposed eCollection 

eComments Requested; Revision of a 

Previously Approved Collection; COPS 

Extension Request Form 

AGENCY: Community Oriented Policing 

Services (COPS) Office, Department of 

Justice. 

ACTION: 60-Day notice. 

SUMMARY: The Department of Justice 

(DOJ), Community Oriented Policing 

Services (COPS) Office, will be 

submitting the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and approval in accordance with 

the Paperwork Reduction Act of 1995. 

DATES: Comments are encouraged and 

will be accepted for 60 days until 

October 19, 2018. 

FOR FURTHER INFORMATION CONTACT: If 

you have additional comments 

especially on the estimated public 

burden or associated response time, 

suggestions, or need a copy of the 

proposed information collection 

instrument with instructions or 

additional information, please contact 

Lashon M. Hilliard, Policy Analyst, 

Department of Justice, Community 

Oriented Policing Services (COPS) 

Office, 145 N Street NE, Washington, DC 

20530 (202–514–6563). 

SUPPLEMENTARY INFORMATION: Written 

comments and suggestions from the 

public and affected agencies concerning 

the proposed collection of information 

are encouraged. Your comments should 

address one or more of the following 

four points: 

—Evaluate whether the proposed 

collection of information is necessary 


daltland on DSKBBV9HB2PROD with NOTICES